Pharmaceutical Contract Development and Manufacturing (CDMO) - Peptides & Oligonucleotides
Strategic Profile
Bachem is building new capacity to manufacture peptides at ton-scale for medicines in urgent demand. The company aims for annual sales of more than CHF 1 billion and an EBITDA margin of over 30% in 2026. With strong organic growth and aggressive capacity expansion, Bachem is positioned as the leading peptide CDMO in a high-growth market segment.
Cyborg Score Rationale
Bachem increased sales in Swiss francs by 4.8% to CHF 605.3 million in 2024, with sales increasing by 5.6% in local currencies. Operating EBITDA increased by 5.7% to CHF 176.3 million with an EBITDA margin of 29.1%. Strong execution on capacity expansion and robust order pipeline support growth trajectory.
Top Insights
Commercial API sales reached CHF 327.0 million with a strong increase in patent-protected peptide sales.
For 2025, Bachem expects growth between 10-15% in local currencies with EBITDA margins in the high twenties.
CHF 292.2 million invested in 2024 with plans for over CHF 400 million CAPEX in 2025, reflecting major capacity buildout.
The company has over 2,200 employees navigating its largest expansion process in company history.
Named Competitors
Lonza — Integrated CDMO with peptide and oligonucleotide capabilities
Ferring — Peptide development and manufacturing services